

Luca Zammataro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477877/publications.pdf>

Version: 2024-02-01

71
papers

3,598
citations

201385

27
h-index

133063

59
g-index

75
all docs

75
docs citations

75
times ranked

6853
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166313.	1.8	2
2	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	2.0	28
3	A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. <i>Cancer Letters</i> , 2021, 496, 84-92.	3.2	7
4	Aurora-A kinase oncogenic signaling mediates TGF- β -induced triple-negative breast cancer plasticity and chemoresistance. <i>Oncogene</i> , 2021, 40, 2509-2523.	2.6	34
5	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48
6	Inactive VEGFR2(R1032Q) exerts pro-oncogenic activity through heterodimerization with wild-type receptor. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
7	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus <i>MLH</i>-1 methylated characteristics (NCT02899793).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5523-5523.	0.8	5
8	Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. <i>Cancer Letters</i> , 2021, 507, 80-88.	3.2	8
9	Abstract 911: In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. , 2021, , .		0
10	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. <i>Gynecologic Oncology</i> , 2021, 163, 334-341.	0.6	10
11	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). <i>Annals of Oncology</i> , 2021, 32, 1045-1046.	0.6	29
12	In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, S186-S187.	0.6	0
13	Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188614.	3.3	2
14	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	2.1	20
15	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	0.6	18
16	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118.	1.3	30
17	Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775.	0.6	2
18	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	1.6	31

#	ARTICLE	IF	CITATIONS
19	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	0.8	32
20	Abstract 5341: Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. , 2020, , .		0
21	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	3.3	52
22	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019, 155, 144-150.	0.6	28
23	Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. <i>Cancers</i> , 2019, 11, 1277.	1.7	24
24	Continuous Glucose Monitoring Linked to an Artificial Intelligence Risk Index: Early Footprints of Intraventricular Hemorrhage in Preterm Neonates. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 146-153.	2.4	7
25	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	3.3	49
26	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164.	0.6	13
27	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17028-e17028.	0.8	1
28	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0
29	Abstract C121: Long Pentraxin-3 modulates bladder cancer progression. , 2019, , .		0
30	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0
31	<i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011.	1.9	25
32	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. <i>Clinical Cancer Research</i> , 2018, 24, 3282-3291.	3.2	44
33	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591.	0.6	53
34	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , 2018, 20, 105.	2.2	58
35	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	3.2	18
36	The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2 ⁺ and CCR5 ⁺ IFN γ -producing γ T cells in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L1010-L1025.	1.3	32

#	ARTICLE	IF	CITATIONS
37	Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. <i>Gynecologic Oncology Reports</i> , 2018, 25, 41-44.	0.3	22
38	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. <i>Medical Oncology</i> , 2017, 34, 91.	1.2	16
39	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186.	0.6	37
40	Polymerase $\hat{\mu}$ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	0.6	55
41	Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 323-333.	1.9	34
42	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152.	0.6	18
43	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845.	3.2	51
44	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009.	0.8	1
45	Abstract 47: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. , 2017, , .		0
46	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. <i>Oncotarget</i> , 2016, 7, 35353-35368.	0.8	34
47	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	3.3	181
48	LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer. <i>BMC Bioinformatics</i> , 2016, 17, 80.	1.2	16
49	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. <i>British Journal of Cancer</i> , 2016, 115, 303-311.	2.9	27
50	Molecular Liaisons between Brain and Cancer: A Hypothesis on the Post-Operative Depression Based on Bioinformatic Evidence. <i>MOJ Proteomics & Bioinformatics</i> , 2015, 2, .	0.1	0
51	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. <i>Frontiers in Immunology</i> , 2014, 5, 128.	2.2	57
52	AnnotateGenomicRegions: a web application. <i>BMC Bioinformatics</i> , 2014, 15, S8.	1.2	8
53	Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis. <i>Bone</i> , 2014, 59, 122-126.	1.4	26
54	Programming Living Machines: The Case Study of Escherichia Coli. <i>Lecture Notes in Computer Science</i> , 2014, , 377-379.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors. <i>Journal of Cell Science</i> , 2013, 126, 3181-91.	1.2	22
56	Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors. <i>Development (Cambridge)</i> , 2013, 140, e1607-e1607.	1.2	0
57	Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. <i>Blood</i> , 2012, 119, 411-421.	0.6	292
58	RANK-dependent autosomal recessive osteopetrosis: Characterization of five new cases with novel mutations. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 342-351.	3.1	66
59	X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. <i>Clinical and Experimental Immunology</i> , 2012, 169, 253-262.	1.1	52
60	AnnotateGenomicRegions: a web application. <i>EMBnet Journal</i> , 2012, 18, 135.	0.2	0
61	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011, 6, 95-102.	1.3	74
62	Large Scale Agent-Based Modeling of the Humoral and Cellular Immune Response. <i>Lecture Notes in Computer Science</i> , 2011, , 15-29.	1.0	3
63	Differential regulation of iron homeostasis during human macrophage polarized activation. <i>European Journal of Immunology</i> , 2010, 40, 824-835.	1.6	337
64	The chemokine system in cancer biology and therapy. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 27-39.	3.2	343
65	Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility. <i>Journal of Immunology</i> , 2010, 185, 642-652.	0.4	337
66	Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. <i>Blood</i> , 2010, 116, 3677-3680.	0.6	163
67	Detecting constituent sequences by means of HP pattern-based grammars to synthesize proteins: Inferring sequence-structure-function relationship. , 2007, , .		0
68	Embryonic cleavage modeling as a computational approach to sphere packing problem. <i>Journal of Theoretical Biology</i> , 2007, 245, 77-82.	0.8	4
69	Type I Collagen Limits VEGFR-2 Signaling by a SHP2 Protein-Tyrosine Phosphatase-Dependent Mechanism 1. <i>Circulation Research</i> , 2006, 98, 45-54.	2.0	55
70	Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. <i>Nature</i> , 2003, 424, 391-397.	13.7	546
71	Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis. <i>Cell Death and Differentiation</i> , 2003, 10, 615-617.	5.0	7